Left Ventricular Hypertrophy Diagnosis and Management
Definition and Diagnosis
- The American College of Cardiology defines left ventricular hypertrophy (LVH) as an abnormal increase in left ventricular wall thickness, typically diagnosed when maximal LV wall thickness is ≥15 mm in adults, or when wall thickness is >2 standard deviations above the mean for age, sex, or body size in children 1, 2
- LVH is most reliably diagnosed using two-dimensional echocardiography, which demonstrates increased LV wall thickness that can be diffuse or segmental in distribution 3
- In adults, LVH is typically defined as maximal wall thickness ≥15 mm, with 13-14 mm considered borderline, particularly when other supporting evidence is present 4
- Cardiovascular magnetic resonance (CMR) is increasingly used for LVH assessment, providing more precise measurements of LV wall thickness and mass 5
Prevalence and Epidemiology
- The estimated prevalence of LVH is approximately 0.2% (1:500) in the general population 4
Pathophysiology and Classification
- Primary LVH is often genetic in origin, as seen in hypertrophic cardiomyopathy (HCM), and may be caused by sarcomeric gene mutations, storage diseases, or mitochondrial disorders 5, 6
- Secondary LVH develops in response to pressure overload, volume overload, or physiologic adaptation, such as athlete's heart 5, 7
Patterns of LVH
- Concentric LVH is characterized by increased wall thickness with normal or decreased LV cavity size, typically seen in pressure overload conditions like hypertension or aortic stenosis 7
- Asymmetric LVH is commonly seen in HCM, with uneven distribution of hypertrophy 5
Differential Diagnosis
- Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by unexplained LVH, typically with preserved or hyperdynamic LV function 6
- Hypertensive heart disease is characterized by LVH secondary to chronic pressure overload 5
- Athlete's heart is a physiologic adaptation to intensive athletic training 5
- Infiltrative/storage disorders, such as Fabry disease or amyloidosis, can also cause LVH 2
Management Considerations
- The American College of Cardiology recommends specific management approaches based on etiology, such as HCM-specific guidelines for those with sarcomeric mutations 6